Search

Background:Stomach cancer is among the most frequent, is a leading cause of mortality in low- and middle-income countries. Assessing its survival is important to guide evidence-based health policies. Aims: To estimate stomach cancer survival in Colombia (2014-2019) with data from the national Cancer Information System (NCIS) and in Cali with data from the Cali Population Cancer Registry (RPCC) (1998-2017). Methods: NCIS estimated the overall 3-year net survival for 8,549 people, while RPCC estimated 5-year net survival for 6,776 people. Results: The 3-year net survival was 36.8% (95% CI: 35.5-38.1). Net survival was higher in people with special insurance (61.7%; 95% CI: 44.8-74.8) or third payer (40.5%; 95% CI: 38.7-42.3) than state insurance (30.7%; 95% CI: 28.7-32.8). It was also higher in women and people diagnosed at early stages. Multivariable analysis showed consistency with survival estimations with a higher risk of death in men, people with state insurance, and diagnosed at advanced stages. In Cali, the 5-year net survival remained stable in men during the last 20 years. In women the 5-year net survival in women increased 8.60 percentage points, equivalent to a 50% increase compared to the 1998-2002 period. For 2013-17, it was 19.1% (95%CI: 16.2-22.2) in men, and 24.8% (95% CI: 20.4-29.3) in women. Conclusions: Population survival estimates from the RPCC were lower than those observed in the NCIS. The differences in their methods and scope can explain variability. Nevertheless, our findings could be complementary to improve cancer control planning in the country.

PURPOSE Population-based survival is a strategic measure of the health system efficiency when managing cancer in a country. By analyzing data from a city in a middle-income country, we aimed to generate further hypotheses about cancer survival that may have a national impact on cancer control. METHODS Cancer cases were collected using the Population-Based Cancer Registry from Cali, Colombia, from 1998 to 2017. We examined the survival of nine cancers or groups of malignancies in patients aged 15-99 years old. The 5-year net survival (NS) was estimated using the Pohar-Perme method. Survival analyses were calculated using the life table method for each calendar year, single year of age, and sex. We used the cohort approach for patients diagnosed in 1998-2012 and the period approach during 2013-2017. RESULTS A total of 59,911 patients were available for analysis. The cancer types included n = 7,460 (12.5%) stomach, n = 6,760 (11.3%) colorectal, n = 6,760 (11.3%) lung, n = 5,164 (8.6%) breast, n = 11,755 (19.6%) cervix, n = 11,284 (18.8%) prostate, n = 4,054 (6.8%) thyroid, n = 2,076 (3.5%) myeloid neoplasia, and n = 6,735 (11.2%) lymphoma. For men, prostate cancer had the highest NS (79.9%-90.1%), whereas thyroid cancer (87.1%-95.7%) in women. Lung and stomach cancer had the lowest survival rate (< 25%) in both sexes. Myeloid neoplasia had the largest variation in survival (15.9%-52.7% for men; 12.5%-49.8% for women), followed by lymphoma (27.6%-55.4% for men; 37.3%-53.4% for women) and colorectal cancer (38.5%-54% for men; 37.1%-55.7% for women). Patients with cervix cancer experienced no change in survival (54.4%-53%) and breast cancer increased approximately 10% (70.8%-81.1%) but remained stable during the last decade. CONCLUSION Our results in survival trends provide insights into the main types of cancer and their burden to the health system. These data contribute to evidence for national cancer prevention policies and the monitoring of the Cancer Control Plan launched by the Colombian government.